KR20160099732A - 백신 요법 - Google Patents

백신 요법 Download PDF

Info

Publication number
KR20160099732A
KR20160099732A KR1020167021791A KR20167021791A KR20160099732A KR 20160099732 A KR20160099732 A KR 20160099732A KR 1020167021791 A KR1020167021791 A KR 1020167021791A KR 20167021791 A KR20167021791 A KR 20167021791A KR 20160099732 A KR20160099732 A KR 20160099732A
Authority
KR
South Korea
Prior art keywords
mice
peptide
aci
amyloid
ts65dn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167021791A
Other languages
English (en)
Korean (ko)
Inventor
안드레아 페이퍼
안드레아스 무스
리메 마다니
파벨 바실리에비치 벨리첸코
윌리엄 모블리
Original Assignee
에이씨 이뮨 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이씨 이뮨 에스.에이. filed Critical 에이씨 이뮨 에스.에이.
Publication of KR20160099732A publication Critical patent/KR20160099732A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020167021791A 2011-09-23 2011-09-23 백신 요법 Ceased KR20160099732A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
USPCT/US2011/052992 2011-09-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137002631A Division KR20160005380A (ko) 2011-09-23 2011-09-23 백신 요법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008710A Division KR102129220B1 (ko) 2011-09-23 2011-09-23 백신 요법

Publications (1)

Publication Number Publication Date
KR20160099732A true KR20160099732A (ko) 2016-08-22

Family

ID=47018510

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167021791A Ceased KR20160099732A (ko) 2011-09-23 2011-09-23 백신 요법
KR1020197008710A Active KR102129220B1 (ko) 2011-09-23 2011-09-23 백신 요법
KR1020137002631A Ceased KR20160005380A (ko) 2011-09-23 2011-09-23 백신 요법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197008710A Active KR102129220B1 (ko) 2011-09-23 2011-09-23 백신 요법
KR1020137002631A Ceased KR20160005380A (ko) 2011-09-23 2011-09-23 백신 요법

Country Status (23)

Country Link
US (2) US20140314837A1 (cg-RX-API-DMAC7.html)
EP (1) EP2758071B1 (cg-RX-API-DMAC7.html)
JP (1) JP6110861B2 (cg-RX-API-DMAC7.html)
KR (3) KR20160099732A (cg-RX-API-DMAC7.html)
CN (2) CN104039346A (cg-RX-API-DMAC7.html)
AU (1) AU2012312126B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014006871A2 (cg-RX-API-DMAC7.html)
CA (1) CA2811188C (cg-RX-API-DMAC7.html)
DK (1) DK2758071T3 (cg-RX-API-DMAC7.html)
EA (1) EA032494B1 (cg-RX-API-DMAC7.html)
ES (1) ES2712951T3 (cg-RX-API-DMAC7.html)
HU (1) HUE041277T2 (cg-RX-API-DMAC7.html)
IL (1) IL231564A0 (cg-RX-API-DMAC7.html)
MX (1) MX350928B (cg-RX-API-DMAC7.html)
MY (1) MY169574A (cg-RX-API-DMAC7.html)
PH (1) PH12014500657A1 (cg-RX-API-DMAC7.html)
PL (1) PL2758071T3 (cg-RX-API-DMAC7.html)
PT (1) PT2758071T (cg-RX-API-DMAC7.html)
SG (1) SG11201400795UA (cg-RX-API-DMAC7.html)
SI (1) SI2758071T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901846T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013044147A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201402071B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽,抗Tau抗体,及其使用方法
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
CN113853214A (zh) * 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗
WO2024156912A1 (en) 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009831A1 (en) 1997-08-28 1999-03-04 Ajay North America Methods and compositions for protecting plants and crops
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
SI2336147T1 (sl) * 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
AU2005290250A1 (en) * 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
CA2690434C (en) * 2007-06-12 2018-05-22 Ac Immune S.A. Monoclonal anti beta amyloid antibody
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
EP2632434B1 (en) * 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties

Also Published As

Publication number Publication date
EP2758071A1 (en) 2014-07-30
EA201400376A1 (ru) 2014-09-30
US20140314837A1 (en) 2014-10-23
EA032494B1 (ru) 2019-06-28
JP2014531455A (ja) 2014-11-27
WO2013044147A1 (en) 2013-03-28
HUE041277T2 (hu) 2019-05-28
AU2012312126A1 (en) 2014-03-27
PT2758071T (pt) 2019-01-11
CN109847058A (zh) 2019-06-07
JP6110861B2 (ja) 2017-04-05
ES2712951T3 (es) 2019-05-16
PH12014500657A1 (en) 2014-05-05
IL231564A0 (en) 2014-04-30
AU2012312126B2 (en) 2016-11-10
PL2758071T3 (pl) 2019-08-30
CA2811188A1 (en) 2013-03-23
MY169574A (en) 2019-04-22
DK2758071T3 (en) 2019-02-18
MX2014003325A (es) 2014-05-21
KR20160005380A (ko) 2016-01-15
NZ622653A (en) 2015-12-24
CA2811188C (en) 2020-04-28
SG11201400795UA (en) 2014-10-30
ZA201402071B (en) 2017-08-30
BR112014006871A2 (pt) 2017-04-04
TR201901846T4 (tr) 2019-03-21
SI2758071T1 (sl) 2019-01-31
US20240270829A1 (en) 2024-08-15
KR102129220B1 (ko) 2020-07-02
MX350928B (es) 2017-09-26
KR20190035948A (ko) 2019-04-03
CN104039346A (zh) 2014-09-10
EP2758071B1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
KR102129220B1 (ko) 백신 요법
US7772375B2 (en) Monoclonal antibodies that recognize epitopes of amyloid-beta
JP5810076B2 (ja) 薬学的組成物
US8603487B2 (en) Palmitoylated AB 1-15 in a liposome as a treatment for amyloid associated diseases
US9289488B2 (en) Vaccine engineering
US8926983B2 (en) Method for improving memory in AD patients
US20120328605A1 (en) Compositions and uses
US20140294849A1 (en) Compositions and uses
US20100285108A1 (en) Method for therapeutic use
JP4934433B2 (ja) 超分子コンストラクトを含む方法および組成物
NZ622653B2 (en) Vaccine therapy for the treatment of memory and/or cognitive impairments in subjects with down’s syndrome
HK1197732A (en) Vaccine therapy
HK1197732B (en) Vaccine therapy

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160809

Application number text: 1020137002631

Filing date: 20130131

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160923

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161115

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181224

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161115

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190326

Application number text: 1020137002631

Filing date: 20130131